{"schema_version":"secwatch.filing_event.v1","accession":"0001411690-23-000080","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.972552+00:00","generated_at":"2026-06-08T09:02:19.454450+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bionano Q3 revenue $9.3M (+29% YoY); $80M convertible notes completed; $33M cost savings plan","bullets":["Q3 revenue $9.3M, +29% YoY; GAAP gross margin 30% vs 25% YoY; non-GAAP operating expense $31.8M.","Completed $80M convertible notes offering (Oct 13), extending cash runway; cash & securities $63.6M.","Cost reduction initiatives expected to save ~$33M annually starting 2024; reiterated FY2023 rev guidance $35-$38M.","Saphyr installed base 301 (+39% YoY); flowcells sold 6,176 (+55% YoY); OGM publications up 61% YoY.","Appointed Gülsen Kama as CFO effective Sept 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001411690-23-000080","json":"https://secwatch.observer/filing/0001411690-23-000080.json","markdown":"https://secwatch.observer/filing/0001411690-23-000080.md","text":"https://secwatch.observer/filing/0001411690-23-000080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/0001411690-23-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/bngo-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:02:19.454450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"593c9face8fa7c2a7c8eb79e1a335627b8b4b358","claim":"Bionano Genomics, Inc. reported third quarter ended September 30, 2023 results: revenue $9.3 million. Guidance reaffirmed.","evidence_excerpt":"Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress • Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022 • Installed base of Saphyr ® systems totaled 301 as of September 30, 2023, which represents a 39% increase over the number of systems installed as of September 30, 2022 • Sold 6,176 nanochannel array flowcells in Q3 2023, which represents a 55% increase over the number of flowcells sold in Q3 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169023000080/0001411690-23-000080-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$9.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}